To date, myeloid-derived suppressor cells (MDSC) have been best studied in cancer, where they represent an escape mechanism for immune surveillance. MDSC are now also gaining interest in the context of transplantation. Suppressive CD11b þ myeloid progenitor cells have been reported to expand endogenously during BM chimerism induction in mice; in particular, in irradiated MHC-matched BM chimeras and in parent-in-F1 BM chimeras. Myeloid cell expansion coincided with a time frame where donor lymphocyte infusion (DLI) therapy-mediated GVL effects without GVHD. Hypothesizing that regulatory myeloid cells may have a role in regulating post-transplant T-cell alloreactivity, we performed a detailed phenotypic and functional characterization of these cells in the parent-in-F1 C57BL/6-[C57BL/6xDBA2] model. We found that transiently expanding CD11b þ myeloid progenitor cells comprise the two phenotypically and functionally distinct mononuclear and polymorphonuclear MDSC subsets that were recently described in tumor-bearing mice. Both MDSC subsets suppressed in vitro and in vivo alloreactive T-cell proliferation. Also, both the subsets mediated enhanced in vitro suppression when harvested from chimeras, given a prior in vivo challenge with non-tolerant donor T cells, indicating that allo-activated T cells can activate MDSC in vivo. This study provides the basis to investigate the---potentially beneficial---role of expanding MDSC in influencing the risk of GVHD during chimerism induction.
INTRODUCTION
Initially described in association with solid tumors, 1,2 myeloidderived suppressor cells (MDSC) are now known to occur in various conditions characterized by immune stimulation such as infection, 3 inflammation 4 and auto-immunity. 5 In mice, MDSC are defined as CD11b þ Gr-1 þ cells, 6 and in humans as Lin À , HLA-DR À , CD11b þ and CD33 þ cells, with variable expression of CD14, CD15 and selected other markers. 7 --9 So far, MDSC have been best studied in cancer, where they represent a well-known mechanism used by solid tumors to escape T-cell immunity. 10 In particular, recent reports have shown the existence of different subtypes of tumor-associated MDSC with distinct phenotype, morphology and, importantly, distinct immunosuppressive mechanisms in humans and mice. 11 --13 MDSC are also gaining interest in transplantation, but contrary to their role in cancer, MDSC may have a beneficial role. It has been demonstrated that exogenous administration of proinflammatory factors such as CpG and LPS induces CD11b þ Gr-1 þ progenitor myeloid cells in mice that, upon adoptive transfer, suppress GVHD 14 and skin allograft rejection, respectively. 15 Such protective effects of adoptively transferred MDSC have also been reported recently for MDSC generated in vitro from embryonic and hematopoietic stem cells. 16, 17 Interestingly, studies in mice have shown that myeloid progenitor cells with suppressive capacity can expand as a physiological bystander phenomenon in the course of BM chimerism induction, suggesting a potential regulating role in the post-transplant immune environment. 18, 19 GVHD still is a major complication of allogeneic hematopoietic SCT (allo-HSCT) in the treatment of various hematological malignancies and often occurs in close association with immune-mediated antitumor responses (GVL). 20 Both GVHD and GVL are known to principally depend on the reactivity of donor T cells against host Ags. The general understanding is that a GVL response is produced when donor T cells target recipient-type Ags on APCs, and tumor cells within the lymphohematopoietic system; when this 'lymphohematopoietic' graft-versus-host (LH-GvH) reactivity extends to the epithelial tissues; however, this leads to GVHD. Donor lymphocyte infusion (DLI), that is, the posttransplant infusion of donor-type non-tolerant lymphocytes, is a strategy used to enhance LH-GvH reactivity and potentiate GVL. However, DLI is also often associated with GVHD. 21 We have previously shown that induction of BM chimerism in irradiated mice is associated with a transient expansion of CD11b þ Gr1 þ cells with in vitro T-cell suppressive activity, the expansion probably being the result of radiation-induced myelosuppression. 18 More recently, we documented a similar expansion of CD11b þ Gr1 þ myeloid progenitor cells in two parent-in-F1 models of chimerism induction. 19 In fact, we showed that a cumulative high-dose challenge with parental C57BL/6 splenocytes in non-irradiated B6DBAF1 and B6SJLF1 recipients induced a state of high-grade multilineage donor chimerism, associated with a transient expansion of CD11b þ Gr-1 þ myeloid progenitor cells. In both these parent-in-F1 and radiation chimeras, challenge with non-tolerant donor T cells (DLI-inoculum) mediated strong LH-GvH reactivity and an anti-tumor response, whereas fatal BM failure-type or epithelial-type GVHD was not seen. Hypothesizing that such regulatory myeloid cells, arising after the transplant, may regulate post-transplant T-cell alloreactivity, here we aimed to characterize this expanding myeloid cell population in more detail. Specifically, we used the previously published parent-in-F1 model 19 to document the existence of phenotypical and/or functional MDSC subsets, to document the in vitro and in vivo immune suppressive behavior of these defined subsets, and lastly, we aimed to document whether T-cell alloreactivity can lead to activation of MDSC in the post-transplant period in vivo.
MATERIALS AND METHODS
d ) mice were purchased from Janvier (Le Genest Saint Isle, France). OT-1 TCR Tg mice were bred in the animal facility of the VUB, Brussels (Belgium), according to the local ethical guidelines. B6DBA2F1 (H-2 b/d ) female mice that were 10 to 12 weeks old were used as recipients, and 6-to 12-week-old C57BL/6 (H-2 b ) female mice as donors. Recipients were housed in groups of five in individually ventilated cages; during procedures animals were kept under laminar flow. Diet consisted of standardized pellet chow and UVdecontaminated water. All experiments were approved by the Ethical Committee for Animal Science of the University of Leuven.
Induction of BM chimerism
Our previously published C57BL/6-F1 hybrid model was used to induce hematopoietic chimerism and CD11b þ Gr1 þ myeloid cell expansion. 19 In this model, non-irradiated B6DBA2F1 recipients were given four i.v. challenges with 25 Â 10 6 C57BL/6 splenocytes each separated by 1 week (day 0, 7, 14 and 21). CD11b þ Gr1 þ MDSC were obtained from spleens of 3-week-old-F1 chimeras by positive selection (CD11b-microbeads þ LS column, Miltenyi Biotec, Bergisch Gladbach, Germany), to test phenotype and/or immunosuppressive function in in vitro and in vivo T-cell alloreactivity assays.
Flow cytometry MDSC (and subsets) were characterized using flow cytometry (FACSCanto, BD Biosciences, Erembodegem, Belgium), with specific Abs against CD3, CD45R/B220, Gr-1, IL4Ra, CD31, Ly6-G, Ly6-C, H-2 b H-2 d CD34 and CD117 (BD Biosciences), and F4/80, CD11c, CD11b and CD115 (eBioscience, Hatfield, UK) after NH 4 Cl treatment. Results were analyzed using BD FACSdiva Software, version 7 (BD Biosciences, Erembodegen, Belgium).
Cell morphology
Morphological characterization of MDSC subtypes was performed on cytospin preparations of FACSorted (FACSaria II, BD Bioscience) MDSC subtypes after May --Gru?nwald --Giemsa staining.
In vitro T-cell alloreactivity assays T-cell2DC culture. Magnetic-activated cell-sorting (MACS)-purified splenic CD11b þ MDSC were added at different suppressor:effector (S:E) ratios to MACS-purified CD4 þ splenic T cells from C57BL/6 mice (300 000 cells/ 100 mL) stimulated with MACS-purified CD11c þ splenic DCs from B6DBA2F1 mice (10 000 cells/100 mL) at a final volume of 280 mL per well in a flat-bottomed 96-well microculture plate in culture medium (RPMI 1640 supplemented with 10% FCS and 5 Â 10 À5 b2-ME (UCB, Brussels, Belgium)) at 37 1C and 5% CO 2 -humidified air. After 2 days, DNA synthesis was assayed by adding 1 mCi (methyl-3H) thymidine (Radio Chemical Centre, Amersham, Buckinghamshire, UK) per well during the last 18 h of culture. Cells were then harvested on glass filter paper, the c.p.m. was determined in a liquid scintillation counter. All conditions were performed in triplicate, and mean c.p.m. was calculated. The stimulation index (SI) was calculated and the level of suppression was then expressed as % suppression of the T-cell proliferation observed in the control condition.
The SI was calculated as (c.p.m. (control proliferation)Àc.p.m. (unstimulated proliferation))/c.p.m. (unstimulated proliferation); % suppression of Tcell proliferation was calculated as (100À (100 Â SI with suppressor/SI without suppressors)).
To study immunosuppressive effects of subtypes of MDSC, these were sorted before testing either using FACSorting (FACSAria II (BD Biosciences)) or using MACSorting based on a previously described protocol for tumorassociated MDSC.
11
Ovalbumin protein (OVA)-specific OT-1 T-cell proliferation assay. The effector mechanisms of MACSorted or FACSorted MDSC subtypes were studied in ovalbumin protein (OVA)-specific T-cell proliferation assays using OT-1 T-cells, as described previously. 11 Briefly, MDSC subtypes were added at different S:E ratios to naive OT-1 splenocytes stimulated with 250 mg/mL chicken OVA (Sigma-Aldrich, St Louis, MO, USA) in a flat- 
In vivo T-cell alloreactivity assay
Popliteal lymph node assay. In vivo suppression was tested in the C57BL/ 6-CB17/SCID popliteal lymph node assay (PLNA) by quantifying the frequency of TCR-Vb3-expressing T cells as donor-derived host-Ag-reactive T cells, as described previously. 22, 23 Briefly, 5 Â 10 6 MACS-purified splenic CD11b þ mouse MDSC were injected with 5 Â 10 6 C57BL/6 T cells in the left footpad of CB17/SCID mice. In the right footpad only 5 Â 10 6 C57BL/6 T cells with medium were injected as control. After 1 week, TCR-Vb3-expressing T-cell frequency was determined in popliteal lymph nodes using flow cytometry.
Statistical analysis
The Mann --Whitney U test and the Wilcoxon rank-sum test were used to estimate the level of statistical significance of difference between groups of data (Po0.05 was considered as evidence for statistical significance).
RESULTS

Induction of mixed chimerism in F1 chimeras is associated with an expansion of donor-derived CD11b
þ Gr-1 þ immature myeloid cells The parent-in-F1 model was used as an experimental system for mixed chimerism induction and DLI. 19 We first quantified myeloid cell expansion in the peripheral blood and the spleens of day-21-F1 chimeras using flow cytometry. The proportion of CD11b þ Gr-1 þ cell expansion in the peripheral blood is shown in Figure 1b . We determined the host vs donor origin of this expanding CD11b þ Gr-1 þ population and found that in spleen a median of 80.7% (range 44.8 --91.7%, n ¼ 9) and in peripheral blood 88.3% (range 37.5 --96.6%, n ¼ 9) of CD11b þ Gr-1 þ cells were donor-derived (representative example shown in Figure 1c ), indicating that these cells originated from donor-type stem cells contained within the splenocyte infusions.
CD11b
þ Gr-1 þ immature myeloid cells in F1 chimeras exert potent suppressive effects on alloreactive T-cell proliferation in vitro and in vivo Next, we investigated whether the expanding CD11b þ Gr-1 þ immature myeloid cells correspond to functionally suppressive MDSC. Hereto, their ability to suppress T-cell proliferation in in vitro and in vivo T-cell alloreactivity assays was tested. Notably, within the CD11b þ cell population, more than 90% of cells are CD11b þ Gr-1 þ double-positive cells, and we therefore used CD11b þ MACS to isolate suppressor cells. First, we added increasing numbers of splenic CD11b þ cells obtained from day-23-F1 chimera to mixed C57BL/6 CD4 þ T-cell 2 B6DBA2F1 CD11c þ DC cultures. As shown in Figure 1d , CD11b þ cells suppressed alloreactive T-cell proliferation in a dose-dependent manner. Second, we tested immunosuppressive effects in vivo using the PLNA. We injected C57BL/6 T-cells with CD11b þ cells MDSC in F1 chimeras comprise mononuclear and polymorphonuclear MDSC subtypes with suppressive activity towards alloreactive T-cell proliferation We next performed a detailed phenotypical and morphological characterization of the CD11b þ Gr-1 þ MDSC population using the definition of MDSC subtypes that was described in tumor-bearing mice. 11 As shown in Figure 2a , the CD11b þ MDSC that expand endogenously in the post-transplant F1 chimera equally comprised two distinct subsets, in particular (SSC 11 Notably, the relative contribution of MOand PMN-MDSC subtypes to the global CD11b þ population was found to be similar in chimeras and control mice (not shown).
We next FACSorted the two MDSC subsets on the basis of Ly6G and Ly6C expression in the CD11b þ B220 À cell population, and subsequent May --Gru?nwald --Giemsa staining showed MO-MDSC to have a MO appearance and PMN-MDSC to have a PMN (doughnut-like) appearance (Figure 2b ). Further phenotyping of MDSC subtypes showed MO-MDSC to be F4/80 int , confirming the MO nature of these cells, 11 whereas PMN-MDSC were F4/80 lo (not shown). To investigate the T-cell suppressive function of each MDSC subtype separately, we added the MACSorted subtypes to mixed T cell2DC cultures as detailed above. As shown in Figure 2c , both MO-MDSC and PMN-MDSC exerted suppressive effects on alloreactive T-cell proliferation in a dose-dependent manner. Consistent with reports on tumor-associated MDSC subtypes, 11 suppression by MO-MDSC was consistently stronger than that exerted by PMN-MDSC (Figure 2c expansion with an additional dose of 50 Â 10 6 non-tolerant C57BL/6 splenocytes (on day 21), in an experimental setting that mimics the clinical practice of DLI. MACSorted MO-and PMN-MDSC were obtained from such F1 chimeras 48 h after in vivo T-cell challenge to test their suppressive function in mixed T cell2DC cultures. F1 chimeras that do not given this additional challenge are referred to as 'non-challenged' control chimeras. As shown in Figure 3 , MO-MDSC and PMN-MDSC from challenged chimeras exhibited stronger suppression than those from non-challenged controls. We conclude that the ex vivo suppressive activity of MO-and PMN-MDSC is enhanced when harvested from chimera, given a prior challenge with non-tolerant donor T-cells.
Suppressive effects of MO, but not PMN-MDSC, involve the production of iNOS As a first step towards deciphering mechanisms, suppressive effects of MO-MDSC and PMN-MDSC were studied in OVA-driven OT-1 T-cell proliferation assays. 11 Notably, in allogeneic T cell2DC cultures, inhibition of iNOS, arginase-1 and HO-1 by L-NMMA, NorNOHA and SnPP, respectively, intrinsically (that is, in the absence of MDSC) influenced the mixed culture reaction, and led to a significant stimulation of T-cell proliferation (not shown). We therefore chose to use the OVA-driven T-cell proliferation assay with OT-1 cells, where addition of these inhibitors did not influence the basal proliferation level (not shown). Consistent with the above-mentioned observed effects in allogeneic T cell2DC cultures, both MDSC subtypes suppressed OVA-driven T-cell proliferation, with more potent effects seen for MO-MDSC than for PMN-MDSC at S:E ratio of 1:1 (Figure 4a ). In these cultures, inhibition of iNOS (by L-NMMA) partially restored MO-MDSC---but not PMN-MDSC---suppression; inhibition of arginase-1 (by NorNOHA) and heme-oxygenase-1 (by SnPP) had no effect (Figure 4b) . The data indicate a role for iNOS in the mechanism of MO-MDSC but not PMN-MDSC immunoregulatory function.
DISCUSSION
In view of the developing opinion that MDSC may have a role in regulating alloreactivity after transplantation, and the recent view in tumor-bearing mice and cancer patients that distinct phenotypic and functional MDSC subsets exist, 11 --13 we have characterized in detail the regulatory myeloid cells that we previously reported to expand as a bystander phenomenon during allo-HSCT in mice. 18, 19 In parent-in-F1 BM chimeras we found that the expanding CD11b þ myeloid cells comprise the typical MO-and PMN-MDSC subtypes recently described in tumor-bearing mice. 11 We demonstrate that both these expanding MDSC subsets have the capacity to regulate alloreactive T-cell responses in vitro and in vivo, and---most importantly---we found that these MDSC subsets were activated in vivo following a challenge with non-tolerant T cells in a chimeric recipient, resulting in enhanced suppressive activity ex vivo towards alloreactive donor T-cell responses. On the basis of these data, we propose that in the current model, in vivo activation of MDSC in the post-transplant period may contribute to keeping the alloreactivity of donor T cells in check, thereby preventing lethal GVHD to occur. Previous studies in mice have shown that LH-GvH reactivity (and antitumor responses) can occur completely dissociated from GVHD, 24 --26 and therefore our data suggest that MDSC may have a regulating role. In the parent-in-F1 setting, we previously showed that a repetitive challenge with parental spleen cells leads to strong LH-GvH reactivity, resulting in a progressive evolution towards high-grade donor chimerism and an antitumor response without fatal BM failure-type GVHD that is known to typically occur in such parent-in-F1 hybrid combination. 19, 27 It should be noted that, besides the potential role of GVHDregulatory myeloid cells, other important mechanisms that influence the reactivity of donor T cells in the post-transplant period are known to exist. First, the pro-inflammatory cytokine storm, produced as a result of the pre-transplant conditioning procedure, 28, 29 enhances recruitment and reactivity of donor T cells. Therefore, when, for example, DLI is given, it is usually given a few weeks or months after the transplant. Also, as time lapses after the transplant, donor chimerism increases and the number of host APCs capable of activating donor T cells declines. Hence, as demonstrated in mouse models, DLI produces enhanced LH-GvH effects in mixed vs full donor chimeras. 25, 30 Our current data support the recently developing view that MDSC may have a role in transplantation. It has been demonstrated that exogenous administration of CpG and G-CSF induces CD11b þ Gr-1 þ MDSC in mice that, upon adoptive transfer into secondary recipients, can suppress GVHD. 14, 31 Having previously shown that chimerism induction in radiation and F1 chimeras is associated with an endogenous expansion of CD11b þ Gr-1 þ myeloid suppressor cells, 18, 19 we now show that these comprise typical MO and PMN CD11b þ Gr-1 þ MDSC subsets, both capable of suppressing in vitro and in vivo T-cell alloresponses. In the current study, we document this in a parent-in-F1 model, where chimerism is induced using parental splenocyte infusions, and we specifically chose this model so as to exclude any interference of conditioning-induced inflammation with the function of MDSC. However, we could also document that the same MDSC subpopulations occur in two models of irradiation-induced chimerism, in particular, MHC-matched miHC-mismatched C3H-AKR chimeras and MHC-mismatched C57BL/6-BALB/c chimeras (data not shown). We assume that the myeloid expansion in these mice results when the BM recovers from being suppressed either by the ionizing damage in the irradiation models or by the hematopoietic GVH reactivity in the parent-in-F1 model. Notably, we here showed a relative MDSC expansion, but from our previous work in the parent-in-F1 model we know that the total spleen and lymph node cell counts are increased in 3-week-old-F1 chimeras (up to 2 --3 fold for spleen cell counts). 19 This indicates that the MDSC expansion represents an absolute increase in these cells in F1 chimeras.
As it is known that GVL responses depend on T-cell reactivity, the question raises whether MDSC also downregulate GVL responses. As regulatory myeloid cells in our allo-HSCT models do not prevent strong LH-GvH responses to occur, 18, 19 and as GVL responses are known to accompany LH-GvH, 20 we assume that they do not interfere with anti-leukemic responses. Supporting this, MacDonald et al. 32 have demonstrated that G-CSF-induced regulatory myeloid cells, upon adoptive transfer, prevent GVHD without compromising GVL in mice. Interestingly, in this respect, Nausch et al. 33 showed that tumor-associated CD11b
þ MDSC that express the RAE-1 ligand actually promote antitumor immune responses by activating natural killer cells to produce high amounts of IFN-g.
The immunosuppressive mechanisms of MDSC are so far incompletely understood but are the subject of intensive investigations, with the overall aim of defining strategies to inhibit the MDSC suppressor activity in diseases, where it is unwanted, such as in cancer. A role for iNOS and arginase-1 has been proven, 34 but involvement of other factors, such as HO-1 15 and transforming growth factor-b, 9 have also been reported. Often, these mediators do not account for the entire suppressor effect, and, conversely, redundancy of different mediators may exist. Our data showed that iNOS is involved in MO-MDSCmediated suppression, which confirms the earlier report on tumorassociated MDSC subtypes. 11 However, also in accordance with literature, we were not able to explain the entire MO-MDSCsuppressive effect, and thus, for PMN-MDSC, the mediators involved remain far undetermined.
The data from this study provide the rationale to explore the role of MDSC and MDSC subsets in the human transplantation setting. Although it is known that in humans, granulocytes are the first cell lineage to recover after allo-HSCT, 35 it has not been studied whether MDSC are induced in recently transplanted allo-HSCT patients. In fact, such studies may be difficult owing to interference by other immune events or treatments typical of the post-transplant period such as infection and treatment with growth factors to accelerate neutrophil recovery. On the other hand, it is known that, despite the approximately 1-loghigher T-cell content of G-CSF-mobilized PBSC grafts relative to conventional BM grafts, the use of G-CSF-mobilized PBSC grafts is not associated with an amplification of acute GVHD. 36 In fact, it has been reported that---in analogy with data in mice 31 ---systemic treatment with G-CSF induces an expansion of myeloid cells with in vitro T-cell suppressive activity; these have so far been broadly characterized as 'suppressive CD14 þ monocytes' 37 or 'activated granulocytes'. 38 Myeloid regulatory cells contained within the G-CSF-mobilized stem cell grafts may control the alloreactivity of donor T cells in the post-transplant period and thereby may contribute to the regulation of GVHD after this type of allo-HSCT. The detailed characterization of these myeloid regulatory cells is the subject of our ongoing investigations.
In conclusion, we investigated the endogenous expansion of regulatory myeloid cells as a bystander phenomenon during BM chimerism induction in mice, and report that these cells comprise the typical MO-and PMN-MDSC that have been described in tumor-bearing mice. Our data indicate that both MDSC subtypes are capable of regulating T-cell alloreactivity, and we found evidence to suggest that these MDSC have a role in modulating the reactivity of adoptively transferred non-tolerant donor T cells, a situation reminiscent of the clinical practice of DLI. These data provide the basis to investigate the role of endogenous MO-and PMN-MDSC---arising in the recipient after the transplant---in influencing the reactivity of donor T cells and the risk of GVHD in the peri-transplant period.
